Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376935 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL2486954 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL16892109 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL15742950 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL20783407 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL26654208 | 1.00 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| Hydrochloric Acid SCHEMBL30143747 | 0.98 | NR1H2 (0.50) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL20159208 | 0.91 | NR1H2 (0.47) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL19916514 | 0.88 | HPGD (0.48) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL16759817 | 0.88 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025081045-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-3746421-B1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023217018-A1 | EZH2 INHIBITOR AND USE THEREOF IN MEDICINE | 贝达药业股份有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023274324-A9 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-10-26 | — | — | WO | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230125481-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| US-20160326161-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-10 | — | — | US | disclosed |
| US-9428495-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-30 | — | — | US | disclosed |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| WO-2015101293-A1 | KINASE INHIBITOR AND USE THEREOF | 山东轩竹医药科技有限公司 | 2015-07-09 | — | — | WO | disclosed |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2057141-B1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2011-10-26 | — | — | EP | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | NR1H2 28/4885USP2 2603/4885SMN1; SMN2 3342/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | NR1H2 919/4885USP2 1960/4885SMN1; SMN2 4318/4885 |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | NR1H2 2286/4885USP2 2952/4885SMN1; SMN2 3902/4885 |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | GSK3B, GSK3A, GSKIP | NR1H2 1418/4885USP2 4029/4885SMN1; SMN2 2121/4885 |
| US-20160326161-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | NR1H2 333/4885USP2 2126/4885SMN1; SMN2 4710/4885 |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | NR1H2 333/4885USP2 2126/4885SMN1; SMN2 4710/4885 |
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | BRCA1, VHL, SF3B5 | NR1H2 2492/4885USP2 3533/4885SMN1; SMN2 784/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | NR1H2 3334/4885USP2 1319/4885SMN1; SMN2 4603/4885 |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | CDK4, CDK6, CDK3 | NR1H2 3595/4885USP2 3732/4885SMN1; SMN2 1498/4885 |
| US-20230125481-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | CRHR2, CRHR1, CRH | NR1H2 104/4885USP2 1621/4885SMN1; SMN2 2016/4885 |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | PARP2, PARP1, PARP4 | NR1H2 3856/4885USP2 4053/4885SMN1; SMN2 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.